Europe Hands Down 2 Critical Drug Decisions

Before you go, we thought you'd like these...
Before you go close icon

In this video, health-care analyst David Williamson takes a closer look at two of the recent European Medicines Agency opinions -- one positive and one negative, even though both drugs have U.S. approval. Watch and find out what it means for Medivation investors and its competitors Johnson & Johnson and Dendreon now that metastatic prostate cancer drug Xtandi received a big thumbs-up from the agency. On the other side of the coin, Pfizer's first-in-class JAK-3 inhibitor for rheumatoid arthritis was knocked on both safety and efficacy, getting hit with a negative opinion. Pfizer's loss may be AbbVie's gain, as its injected best-selling RA drug, Humira, won't have to face an oral competitor.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.


The article Europe Hands Down 2 Critical Drug Decisions originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends Johnson & Johnson and owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners